The new paradigm of systemic therapies for metastatic melanoma - 14/12/17
Abstract |
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Le texte complet de cet article est disponible en PDF.Key words : immune therapy, metastatic melanoma, targeted therapy
Abbreviations used : APC, BRAF, CRR, CTLA-4, irAEs, KA, LDH, MAPK, MHC, MM, OS, PD-1, PFS, PI3K, SCC
Plan
Dr Volpe and Mr Klufas contributed to this work equally. |
|
Drs Hegde and Grant-Kels contributed to this work equally. |
|
Funding sources: Supported by Jane and Richard Lublin. |
|
Reprints not available from the authors. |
|
Conflicts of interest: None declared. |
Vol 77 - N° 2
P. 356-368 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?